Skip to main content

Table 3 Correlations between the ΔSUV and the clinical parameters

From: Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT

   3 months
   ΔDAS28 ΔDAS28-CRP ΔSDAI ΔCDAI
ΔSUV (12 joints) r 0.615* 0.696* 0.652* 0.662*
p 0.009 0.002 0.005 0.004
ΔSUV (8 joints) r 0.61* 0.723* 0.637* 0.64*
  p 0.009 0.001 0.006 0.006
   6 months
   ΔDAS28 ΔDAS28-CRP ΔSDAI ΔCDAI
ΔSUV (12 joints) r 0.775* 0.828* 0.686* 0.711*
p <0.001 <0.001 0.002 0.001
ΔSUV (8 joints) r 0.749* 0.775* 0.623* 0.686*
  p 0.001 <0.001 0.008 0.002
  1. The ΔSUV (12/8 joints), the difference in the total SUVmax of the affected 12 or eight (bilateral shoulder, elbow, wrist and knee) joints before and after treatment, was significantly correlated with the ΔDAS28, ΔDAS28-CRP, ΔSDAI and ΔCDAI. *indicates a significant correlation following the Bonferroni correction.